Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opicapone Add-on to LCIG in Parkinson's Disease
NCT06432309Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Ferrara
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of opicapone in Parkinson's disease (PD) (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Ferrara. Primary endpoints: Evaluation of motor fluctuations changes at 12 months and Evaluation of dyskinesia changes at 12 months. Started Jul 2022; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06432309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06432309.